Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

NCT00674791 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

BIOLOGICAL: OCPM Immunotherapeutic Vaccine

Sponsor

Duke University

Collaborators

[object Object]